Goldfinch’s $100M round sets up Third Rock company to advance kidney disease therapies

With $100 million in series B funding, Goldfinch Bio Inc. aims to move its second kidney disease therapy into the clinic and begin Phase II testing of

Read the full 271 word article

How to gain access

Continue reading with a
two-week free trial.